Abstract
Enveloped animal viruses fuse their membrane with a host cell membrane in order to deliver their genome into the cytoplasm of the cell and thus initiating infection. This crucial step is mediated by virally encoded transmembrane proteins that, following an appropriate triggering, insert their fusion peptides into the target membrane and, through a cascade of conformational changes, drive the merging of the two apposing membranes. The battle against viruses is ongoing with the constant threat of viruses developing resistance to present drugs and emerging viruses, therefore there is a continuous challenge to improve our defence strategies. Entry inhibitors are currently in development for diverse human and animal viral pathogens, and advances in our understanding on how viral entry proteins undergo conformational changes that lead to entry offer a huge potential for the development of novel therapeutics. This review describes recent advances on viralmediated fusion mechanisms concentrating on the development of peptidic inhibitors of membrane fusion.
Keywords: Membrane fusion, viral fusion peptide, viral inhibitor, heptad repeat, fusion peptide, glycoprotein
Protein & Peptide Letters
Title: Inhibition of Viral-Induced Membrane Fusion by Peptides
Volume: 16 Issue: 7
Author(s): Mariaterasa Vitiello, Marilena Galdiero and Massimiliano Galdiero
Affiliation:
Keywords: Membrane fusion, viral fusion peptide, viral inhibitor, heptad repeat, fusion peptide, glycoprotein
Abstract: Enveloped animal viruses fuse their membrane with a host cell membrane in order to deliver their genome into the cytoplasm of the cell and thus initiating infection. This crucial step is mediated by virally encoded transmembrane proteins that, following an appropriate triggering, insert their fusion peptides into the target membrane and, through a cascade of conformational changes, drive the merging of the two apposing membranes. The battle against viruses is ongoing with the constant threat of viruses developing resistance to present drugs and emerging viruses, therefore there is a continuous challenge to improve our defence strategies. Entry inhibitors are currently in development for diverse human and animal viral pathogens, and advances in our understanding on how viral entry proteins undergo conformational changes that lead to entry offer a huge potential for the development of novel therapeutics. This review describes recent advances on viralmediated fusion mechanisms concentrating on the development of peptidic inhibitors of membrane fusion.
Export Options
About this article
Cite this article as:
Vitiello Mariaterasa, Galdiero Marilena and Galdiero Massimiliano, Inhibition of Viral-Induced Membrane Fusion by Peptides, Protein & Peptide Letters 2009; 16 (7) . https://dx.doi.org/10.2174/092986609788681742
DOI https://dx.doi.org/10.2174/092986609788681742 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Vitamin A Deficiency and Opioids on Parvalbumin + Interneurons in the Hippocampus of the HIV-1 Transgenic Rat
Current HIV Research Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Multiple Sclerosis (MS): A Critical Review
CNS & Neurological Disorders - Drug Targets Viral Inactivation Based on Inhibition of Membrane Fusion: Understanding the Role of Histidine Protonation to Develop New Viral Vaccines
Protein & Peptide Letters The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Current Neuropharmacology A Clinical Perspective: Anti Taus Treatment in Alzheimers Disease
Current Alzheimer Research Aptamers: Selection, Modification and Application to Nervous System Diseases
Current Medicinal Chemistry Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Cytomegalovirus Infection in Pediatric Immunocompromised Hosts
Infectious Disorders - Drug Targets Effective Biomarkers for Proof-of-Concept
Current Medical Imaging Risk Factors for Different Grades of Lower Respiratory Tract Infections in Children Under Five Years Old with Measles: Based on Chest Radiography
Current Medical Imaging Overview on the Tricks of HIV Tat to Hit the Blood Brain Barrier
Current HIV Research Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of VE-cadherin in Blood-brain Barrier Integrity Under Central Nervous System Pathological Conditions
Current Neuropharmacology Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry Autoantibodies Among HIV-1 Infected Individuals and the Effect of Anti-Retroviral Therapy (ART) on It
Current HIV Research Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research